Proton pump inhibitors: new mechanisms of action.

08:00 EDT 13th April 2019 | BioPortfolio

Summary of "Proton pump inhibitors: new mechanisms of action."

Proton pump inhibitors (PPIs) are drugs widely used to potently suppress gastric acid secretion in the therapy of gastroesophageal diseases. These drugs are activated in the acidic environment of the stomach and bind covalently to sulfhydryl groups of cysteines found in the proton pump (an H ,K -ATPase) inactivating it. This effect is irreversible and new H ,K -ATPase needs to be expressed in order to resume acid secretion. This article is protected by copyright. All rights reserved.


Journal Details

This article was published in the following journal.

Name: Basic & clinical pharmacology & toxicology
ISSN: 1742-7843


DeepDyve research library

PubMed Articles [12685 Associated PubMed Articles listed on BioPortfolio]

Proton Pump Inhibitors and the Risk of Dementia: is There a Link?

Dementia is one of the most common neurodegenerative disorder among older populations around the world, and the incidence is increasing. Many epidemiologic studies have considered the association betw...

Neutropenia and Thrombocytopenia Induced by Proton Pump Inhibitors: A Case Report.

An 85-year-old man was admitted to our hospital because of dysphagia, and was diagnosed with benign stricture of the esophagus. He was hospitalized repeatedly for balloon dilations. Pantoprazole sodiu...

Risk of Gynecomastia with Users of Proton Pump Inhibitors.

Proton pump inhibitors (PPI) are commonly prescribed for many gastrointestinal diseases. A number of case reports have linked PPIs to gynecomastia in men, but large epidemiologic studies are lacking.

Does the use of proton pump inhibitors increase the risk of hypomagnesemia: An updated systematic review and meta-analysis.

Proton pump inhibitors (PPIs) are commonly used in the treatment of acid-related diseases; however, the association between the use of PPIs and potential risk of hypomagnesemia is controversial.

Outcome of stroke patients on clopidogrel plus proton-pump inhibitors: a single-center cohort study.

Recent studies suggest a higher risk of adverse cardiovascular outcome and mortality in patients co-prescribed clopidogrel with proton pump inhibitors (PPI).

Clinical Trials [5002 Associated Clinical Trials listed on BioPortfolio]

Proton Pump Inhibitors Use in Patients With Psoriasis

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action wit...

Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice

The primary purpose of the study is to determine the effect of esomeprazole compared to placebo in patients from general practice who have previously been treated with proton-pump-inhibito...

The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.

Study to provide initial data to assess the safety and efficacy of tegaserod use in patients with dyspepsia that are being treated with proton pump inhibitors (PPI's) for heartburn.

Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel

The purpose of this study is to assess, whether the administration of a proton pump inhibitor, Rabeprazole, has a negative effect on the activity of a concomitantly administered blood thin...

Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers

This is a research study that will investigate the effects of proton pump inhibitors (often used to treat stomach upset) on Gleevec® (a drug that is FDA-approved to treat some types of ca...

Medical and Biotech [MESH] Definitions

Integral membrane proteins that transport protons across a membrane. This transport can be linked to the hydrolysis of ADENOSINE TRIPHOSPHATE. What is referred to as proton pump inhibitors frequently is about POTASSIUM HYDROGEN ATPASE.

Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX.

A cytochrome P-450 enzyme subtype that oxidizes several important groups of drugs including many PROTON PUMP INHIBITORS and ANTICONVULSANTS.

Chronic ESOPHAGITIS characterized by esophageal mucosal EOSINOPHILIA. It is diagnosed when an increase in EOSINOPHILS are present over the entire esophagus. The reflux symptoms fail to respond to PROTON PUMP INHIBITORS treatment, unlike in GASTROESOPHAGEAL REFLUX DISEASE. The symptoms are associated with IgE-mediated hypersensitivity to food or inhalant allergens.

Compounds that contain benzimidazole joined to a 2-methylpyridine via a sulfoxide linkage. Several of the compounds in this class are ANTI-ULCER AGENTS that act by inhibiting the POTASSIUM HYDROGEN ATPASE found in the PROTON PUMP of GASTRIC PARIETAL CELLS.

Quick Search


DeepDyve research library

Searches Linking to this Article